Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 1/2015

01-02-2015

NS5ATP9 Suppresses Activation of Human Hepatic Stellate Cells, Possibly via Inhibition of Smad3/Phosphorylated-Smad3 Expression

Authors: Mengran Zhang, Jinqian Zhang, Shunai Liu, Qi Wang, Guoxian Lin, Rongxian Qiu, Min Quan, Jun Cheng

Published in: Inflammation | Issue 1/2015

Login to get access

Abstract

Activation of hepatic stellate cell (HSC) is the central event in liver fibrosis. NS5ATP9 is related to many malignant tumors, but little is known about its function in HSC activation. The aim of this study is to investigate the role of NS5ATP9 in HSC activation in vitro. Genes related to liver fibrosis were detected after NS5ATP9 overexpression or silencing with or without transforming growth factor (TGF)-β1 stimulation in the human HSCs by real-time polymerase chain reaction and western blotting. Cell proliferation, migration, and apoptosis were tested, and the mechanisms underlying the effect of NS5ATP9 on HSC activation were studied. We showed that NS5ATP9 suppressed HSC activation and collagen production, with or without TGF-β1 induction. Also, NS5ATP9 inhibited cell proliferation and migration and promoted apoptosis. Furthermore, NS5ATP9 reduced basal and TGF-β1-mediated Smad3/phosphorylated-Smad3 expression. The existence of a physical complex between NS5ATP9 and Smad3 was illustrated. NS5ATP9 suppresses HSC activation, extracellular matrix production, and promotes apoptosis, in part through reducing Smad3/phosphorylated-Smad3 expression.
Appendix
Available only for authorised users
Literature
1.
2.
Mahato, R.I., K. Cheng, and R.V. Guntaka. 2005. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opinion on Drug Delivery 2: 3–28.CrossRefPubMed
3.
4.
5.
Piek, E., C.H. Heldin, and D.P. Ten. 1999. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB Journal 13: 2105–2124.PubMed
6.
Massague, J. 2000. How cells read TGF-beta signals. Nature Reviews Molecular Cell Biology 1: 169–178.CrossRefPubMed
7.
Yu, P., B. Huang, M. Shen, et al. 2001. p15(PAF), a novel PCNA associated factor with increased expression in tumor tissues. Oncogene 20: 484–489.CrossRefPubMed
8.
Shi, L., S.L. Zhang, K. Li, et al. 2008. NS5ATP9, a gene up-regulated by HCV NS5A protein. Cancer Letters 259: 192–197.CrossRefPubMed
9.
Kato, T., Y. Daigo, M. Aragaki, K. Ishikawa, M. Sato, and M. Kaji. 2012. Overexpression of KIAA0101 predicts poor prognosis in primary lung cancer patients. Lung Cancer 75: 110–118.CrossRefPubMed
10.
Liu, L., X. Chen, S. Xie, C. Zhang, Z. Qiu, and F. Zhu. 2012. Variant 1 of KIAA0101, overexpressed in hepatocellular carcinoma, prevents doxorubicin-induced apoptosis by inhibiting p53 activation. Hepatology 56: 1760–1769.CrossRefPubMed
11.
Li, K., Q. Ma, L. Shi, et al. 2008. NS5ATP9 gene regulated by NF-kappaB signal pathway. Archives of Biochemistry and Biophysics 479: 15–9.CrossRefPubMed
12.
Mizutani, K., M. Onda, S. Asaka, et al. 2005. Overexpressed in anaplastic thyroid carcinoma-1 (OEATC-1) as a novel gene responsible for anaplastic thyroid carcinoma. Cancer 103: 1785–1790.CrossRefPubMed
13.
Yuan, R.H., Y.M. Jeng, H.W. Pan, et al. 2007. Overexpression of KIAA0101 predicts high stage, early tumor recurrence, and poor prognosis of hepatocellular carcinoma. Clinical Cancer Research 13: 5368–5376.CrossRefPubMed
14.
Emanuele, M.J., A. Ciccia, A.E. Elia, and S.J. Elledge. 2011. Proliferating cell nuclear antigen (PCNA)-associated KIAA0101/PAF15 protein is a cell cycle-regulated anaphase-promoting complex/cyclosome substrate. Proceedings of the National Academy of Sciences of the United States of America 108: 9845–9850.CrossRefPubMedCentralPubMed
15.
Turchi, L., M. Fareh, E. Aberdam, et al. 2009. ATF3 and p15PAF are novel gatekeepers of genomic integrity upon UV stress. Cell Death and Differentiation 16: 728–737.CrossRefPubMed
16.
Quan M, Liu S, Li G, et al. 2013. A functional role for NS5ATP9 in the induction of HCV NS5A-mediated autophagy. J Viral Hepat, accepted.
17.
Xu, L., A.Y. Hui, E. Albanis, et al. 2005. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142–151.CrossRefPubMedCentralPubMed
18.
Chen, Y.L., J. Lv, X.L. Ye, et al. 2011. Sorafenib inhibits transforming growth factor beta1-mediated epithelial–mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology 53: 1708–1718.CrossRefPubMed
19.
Xiao, X., Y. Gang, Y. Gu, et al. 2012. Osteopontin contributes to TGF-beta1 mediated hepatic stellate cell activation. Digestive Diseases and Sciences 57: 2883–2891.CrossRefPubMed
20.
Shimada, H., N.R. Staten, and L.E. Rajagopalan. 2011. TGF-beta1 mediated activation of Rho kinase induces TGF-beta2 and endothelin-1 expression in human hepatic stellate cells. Journal of Hepatology 54: 521–528.CrossRefPubMed
21.
Lim, J.Y., M.A. Oh, W.H. Kim, H.Y. Sohn, and S.I. Park. 2012. AMP-activated protein kinase inhibits TGF-beta-induced fibrogenic responses of hepatic stellate cells by targeting transcriptional coactivator p300. Journal of Cellular Physiology 227: 1081–1089.CrossRefPubMed
22.
23.
Shi, Y., and J. Massague. 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685–700.CrossRefPubMed
24.
Massague, J., and Y.G. Chen. 2000. Controlling TGF-beta signaling. Genes and Development 14: 627–644.PubMed
25.
26.
Lotersztajn, S., B. Julien, F. Teixeira-Clerc, P. Grenard, and A. Mallat. 2005. Hepatic fibrosis: molecular mechanisms and drug targets. Annual Review of Pharmacology and Toxicology 45: 605–628.CrossRefPubMed
27.
28.
Jain, M., L. Zhang, E.E. Patterson, and E. Kebebew. 2011. KIAA0101 is overexpressed, and promotes growth and invasion in adrenal cancer. PLoS ONE 6: e26866.CrossRefPubMedCentralPubMed
29.
Hosokawa, M., A. Takehara, K. Matsuda, et al. 2007. Oncogenic role of KIAA0101 interacting with proliferating cell nuclear antigen in pancreatic cancer. Cancer Research 67: 2568–2576.CrossRefPubMed
30.
Guo, M., J. Li, D. Wan, and J. Gu. 2006. KIAA0101 (OEACT-1), an expressionally down-regulated and growth-inhibitory gene in human hepatocellular carcinoma. BMC Cancer 6: 109.CrossRefPubMedCentralPubMed
31.
Wang, Q., Y. Wang, Y. Li, X. Gao, S. Liu, and J. Cheng. 2013. NS5ATP9 contributes to inhibition of cell proliferation by hepatitis C virus (HCV) nonstructural protein 5A (NS5A) via MEK/extracellular signal regulated kinase (ERK) pathway. International Journal of Molecular Sciences 14: 10539–10551.CrossRefPubMedCentralPubMed
32.
Simpson, F., K.L. Lammerts van Bueren, N. Butterfield, et al. 2006. The PCNA-associated factor KIAA0101/p15(PAF) binds the potential tumor suppressor product p33ING1b. Experimental Cell Research 312: 73–85.CrossRefPubMed
Metadata
Title
NS5ATP9 Suppresses Activation of Human Hepatic Stellate Cells, Possibly via Inhibition of Smad3/Phosphorylated-Smad3 Expression
Authors
Mengran Zhang
Jinqian Zhang
Shunai Liu
Qi Wang
Guoxian Lin
Rongxian Qiu
Min Quan
Jun Cheng
Publication date
01-02-2015
Publisher
Springer US
Published in
Inflammation / Issue 1/2015
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-0031-y

Other articles of this Issue 1/2015

Inflammation 1/2015 Go to the issue

OriginalPaper

Anti-Inflammatory Effects of Recombinant Human PDCD5 (rhPDCD5) in a Rat Collagen-Induced Model of Arthritis

OriginalPaper

Oral Administration of Saccharomyces boulardii Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats via Reducing Intestinal Permeability and Modulating Gut Microbial Composition

OriginalPaper

CCR5 Blockade Promotes M2 Macrophage Activation and Improves Locomotor Recovery After Spinal Cord Injury in Mice

OriginalPaper

Intra-articular (IA) Ropivacaine Microparticle Suspensions Reduce Pain, Inflammation, Cytokine, and Substance P Levels Significantly More than Oral or IA Celecoxib in a Rat Model of Arthritis

OriginalPaper

Magnolol Inhibits the Inflammatory Response in Mouse Mammary Epithelial Cells and a Mouse Mastitis Model

OriginalPaper

Attenuation of Morphine Analgesic Tolerance by Rosuvastatin in Naïve and Morphine Tolerance Rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits